BPMC: Blueprint Medicines Net earnings per share for the last 12 months

Symbol and logo of brand Blueprint Medicines Corp. (BPMC)

Blueprint Medicines (BPMC) revenues are based on insurance company procurement for the treatment of rare tumors. However, geopolitical barriers complicate international trials, while promotion costs for Ayvakit and R&D expenditures pressure capital. The EPS trend over the last 12 months demonstrates profit inertia, with the latest figure standing at -2.47, highlighting stable demand alongside the risk of stagnant growth.

BPMC (Blueprint Medicines) Net earnings per share (EPS TTM) history from 07/04/2022 to 08/02/2025

Analytical breakdowns for Blueprint Medicines

Basic company analysis:blueprintmedicines.com - BPMC
Manufactured products of Blueprint Medicines Corp.

Stable demand for patented rare blood disease therapies at Blueprint Medicines (BPMC) directly drives the business's per-share income dynamics. This metric is calculated as the ratio of net income to the total number of shares, reflecting the actual earnings per share. By analyzing the trailing twelve-month net income per share, an investor can see the actual efficiency of monetizing medical innovations. Growth in this metric confirms the scalability of profits relative to operating expenses. A positive trend on this chart signals the long-term fundamental stability of Blueprint Medicines (BPMC).

Who Blueprint Medicines competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (Exelixis Corp)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|GlycoMimetics Inc. - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics, Inc) - Net earnings per share (EPS TTM)